FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 609 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Beauty, Healing and Space January 27, 2021 Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... June 19, 2023 Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... October 12, 2023 Load more HOT NEWS CancerLand Bookshelf : Loosen Prostate Cancer Anal Cancer Incidence and Deaths Are Rising in the United States EMA Recommends Extension of Indications for Durvalumab in the Management of...
